TY  - JOUR
AU  - Carmona-Bayonas, Alberto 
AU  - Valle, Juan 
AU  - García Carbonero, Rocío
PY  - 2019
DO  - 10.1200/jco.19.00980
SN  - 0732-183X
UR  - https://hdl.handle.net/20.500.14352/117140
T2  - JOURNAL OF CLINICAL ONCOLOGY
AB  - PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current...
LA  - eng
M2  - 2571
PB  - AMER SOC CLINICAL ONCOLOGY
KW  - Tumores neuroendocrinos
KW  - Supervivencia sin progresión
KW  - Somatostatina
KW  - Hormonas / farmacología
TI  - Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
TY  - journal article
VL  - 37
ER  -